Clinical Trial Update: A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS) [Phase 3]

View source ↗

Summary

Phase 3 trial of TEV-50717 for Tourette syndrome completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• TEV-50717

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Tourette Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2020-06-09